Diabetes drug company Takeda Pharmaceutical Co this week announced that it had applied for approval to market a joint diabetes treatment in the United States. The drug, which combines SYR-332 and blockbuster drug Actos, is available as a single tablet.
Actos, which will lose patent protection in America in 2011, has been a bestseller for Takeda. A spokeswoman for the company, Ayako Iwamuro, reportedly commented: “It is the world’s first drug combining alogliptin (the generic name of SYR-322) and pioglitazone (the generic name of Actos). We see this providing us with a major foothold in coping with the impact of the patent expiry for Actos.”
The earliest that the pharmaceutical company will get a decision on their drug will be in 10 months time.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…